Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $8.5 million.

  • Champions Oncology's Cash & Equivalents rose 20922.29% to $8.5 million in Q4 2025 from the same period last year, while for Oct 2025 it was $8.5 million, marking a year-over-year increase of 20922.29%. This contributed to the annual value of $9.8 million for FY2025, which is 27375.86% up from last year.
  • According to the latest figures from Q4 2025, Champions Oncology's Cash & Equivalents is $8.5 million, which was up 20922.29% from $10.3 million recorded in Q3 2025.
  • Over the past 5 years, Champions Oncology's Cash & Equivalents peaked at $11.6 million during Q1 2023, and registered a low of $2.6 million during Q2 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $6.5 million (2021), whereas its average is $6.7 million.
  • As far as peak fluctuations go, Champions Oncology's Cash & Equivalents tumbled by 7412.53% in 2024, and later skyrocketed by 27375.86% in 2025.
  • Quarter analysis of 5 years shows Champions Oncology's Cash & Equivalents stood at $4.8 million in 2021, then skyrocketed by 125.54% to $10.8 million in 2022, then crashed by 49.08% to $5.5 million in 2023, then crashed by 50.05% to $2.8 million in 2024, then surged by 209.22% to $8.5 million in 2025.
  • Its last three reported values are $8.5 million in Q4 2025, $10.3 million for Q3 2025, and $9.8 million during Q2 2025.